New cancer drug MBS8(1V270) enters first human trials
NCT ID NCT04855435
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing an experimental drug called MBS8(1V270), given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 106 participants will be enrolled, and the study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MBS8(1V270) (an experimental drug) and pembrolizumab (an immunotherapy)
What this could lead to
If it works, this could point toward a new treatment option for advanced solid tumors that have stopped responding to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 106 participants, so it is primarily testing safety, not effectiveness. The drug may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centro Integral Oncológico Clara Campal (CIOCC)
RECRUITINGMadrid, 28050, Spain
Contact
-
Consorcio Hospital General Universitario de Valencia
RECRUITINGValencia, Spain
Contact
-
Fundacion Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (FJD)
RECRUITINGMadrid, 28015, Spain
Contact
-
Herlev and Gentofte Hospital, Center for Cancer Research
RECRUITINGHerlev, DK-2730, Denmark
Contact
-
Institut Catalá de Oncologia - Hospital Duran i Reynals.
NOT_YET_RECRUITINGBarcelona, Spain
Contact